92 related articles for article (PubMed ID: 26416047)
21. Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1-pRB-E2F1 pathway.
Wang J; Zhang J; Ma Q; Zhang S; Ma F; Su W; Zhang T; Xie X; Di C
J Cell Mol Med; 2023 Apr; 27(7):991-1005. PubMed ID: 36915230
[TBL] [Abstract][Full Text] [Related]
22. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk.
Liu B; Zhang Y; Jin M; Ni Q; Liang X; Ma X; Yao K; Li Q; Chen K
Mol Carcinog; 2010 Jan; 49(1):75-84. PubMed ID: 19795398
[TBL] [Abstract][Full Text] [Related]
23. Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients.
Hsia TC; Liu CJ; Lin CH; Chang WS; Chu CC; Hang LW; Lee HZ; Lo WC; Bau DT
Anticancer Res; 2011 Oct; 31(10):3601-5. PubMed ID: 21965784
[TBL] [Abstract][Full Text] [Related]
24. Requirement for CDK4 kinase function in breast cancer.
Yu Q; Sicinska E; Geng Y; Ahnström M; Zagozdzon A; Kong Y; Gardner H; Kiyokawa H; Harris LN; Stål O; Sicinski P
Cancer Cell; 2006 Jan; 9(1):23-32. PubMed ID: 16413469
[TBL] [Abstract][Full Text] [Related]
25. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer.
Jain M; Kumar S; Lal P; Tiwari A; Ghoshal UC; Mittal B
Cancer Detect Prev; 2007; 31(3):225-32. PubMed ID: 17561354
[TBL] [Abstract][Full Text] [Related]
26. Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas.
Lewis RC; Bostick RM; Xie D; Deng Z; Wargovich MJ; Fina MF; Roufail WM; Geisinger KR
Cancer Res; 2003 Dec; 63(23):8549-53. PubMed ID: 14679024
[TBL] [Abstract][Full Text] [Related]
27. Genetic variant of CCND1: association with HPV-mediated cervical cancer in Indian population.
Thakur N; Hussain S; Kohaar I; Tabassum R; Nasare V; Tiwari P; Batra S; Bhambhani S; Das BC; Basir SF; Bharadwaj D; Bharadwaj M
Biomarkers; 2009 Jun; 14(4):219-25. PubMed ID: 19489683
[TBL] [Abstract][Full Text] [Related]
28. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis.
Xu XL; Chen SZ; Chen W; Zheng WH; Xia XH; Yang HJ; Li B; Mao WM
Breast Cancer Res Treat; 2013 Jun; 139(2):329-39. PubMed ID: 23670132
[TBL] [Abstract][Full Text] [Related]
29. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma.
Casson AG; Zheng Z; Evans SC; Geldenhuys L; van Zanten SV; Veugelers PJ; Porter GA; Guernsey DL
Cancer; 2005 Aug; 104(4):730-9. PubMed ID: 15971196
[TBL] [Abstract][Full Text] [Related]
30. Association of cyclin D1 genotypes with nasopharyngeal carcinoma risk.
Shih LC; Tsai CW; Tsai MH; Tsou YA; Chang WS; Li FJ; Lee MH; Bau DT
Anticancer Res; 2012 Mar; 32(3):1093-8. PubMed ID: 22399638
[TBL] [Abstract][Full Text] [Related]
31. [The association of cyclin D1 (A870G) polymorphism with susceptibility to esophageal and cardiac cancer in north Chinese population].
Wang R; Zhang JH; Li Y; Wen DG; He M; Wei LZ
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1089-92. PubMed ID: 12899785
[TBL] [Abstract][Full Text] [Related]
32. Cyclin D1 polymorphism and the risk of endometrial cancer.
Kang S; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2005 May; 97(2):431-5. PubMed ID: 15863141
[TBL] [Abstract][Full Text] [Related]
33. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
34. Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women.
Jeon YT; Kim JW; Song JH; Park NH; Song YS; Kang SB; Lee HP
Cancer Lett; 2005 Jun; 223(2):259-63. PubMed ID: 15896460
[TBL] [Abstract][Full Text] [Related]
35. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract.
Buch S; Zhu B; Davis AG; Odom D; Siegfried JM; Grandis JR; Romkes M
Mol Carcinog; 2005 Apr; 42(4):222-8. PubMed ID: 15754315
[TBL] [Abstract][Full Text] [Related]
36. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
37. A case-control study of cyclin D1 CCND1 870A-->G polymorphism and bladder cancer.
Cortessis VK; Siegmund K; Xue S; Ross RK; Yu MC
Carcinogenesis; 2003 Oct; 24(10):1645-50. PubMed ID: 12896908
[TBL] [Abstract][Full Text] [Related]
38. CCND1 polymorphisms (A870G and C1722G) modulate its protein expression and survival in oral carcinoma.
Sathyan KM; Nalinakumari KR; Abraham T; Kannan S
Oral Oncol; 2008 Jul; 44(7):689-97. PubMed ID: 18061526
[TBL] [Abstract][Full Text] [Related]
39. Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma.
Holley SL; Matthias C; Jahnke V; Fryer AA; Strange RC; Hoban PR
Oral Oncol; 2005 Feb; 41(2):156-60. PubMed ID: 15695117
[TBL] [Abstract][Full Text] [Related]
40. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan.
Huang WS; Tang R; Lin PY; Changchien CR; Chen JS; Chiang JM; Yeh CY; Wang JY; Hsieh LL
Dis Colon Rectum; 2006 May; 49(5):602-8. PubMed ID: 16552496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
